Switch theme
Sign up to access all valuation multiples
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The company’s core products are dental implants, and it holds roughly one third of the global implant dentistry market, which is estimated to be worth roughly CHF 5.4 billion. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
1954
11.8K+
LTM Revenue $2.9B
LTM EBITDA $908M
$17.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Straumann Group has a last 12-month revenue of $2.9B and a last 12-month EBITDA of $908M.
In the most recent fiscal year, Straumann Group achieved revenue of $2.8B and an EBITDA of $821M.
Straumann Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Straumann Group valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.7B | $2.8B | XXX | XXX | XXX |
| Gross Profit | $2.0B | $2.0B | XXX | XXX | XXX |
| Gross Margin | 73% | 71% | XXX | XXX | XXX |
| EBITDA | $559M | $821M | XXX | XXX | XXX |
| EBITDA Margin | 20% | 29% | XXX | XXX | XXX |
| Net Profit | $492M | $278M | XXX | XXX | XXX |
| Net Margin | 18% | 10% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Straumann Group's stock price is CHF 97 (or $110).
Straumann Group has current market cap of CHF 15.5B (or $17.5B), and EV of CHF 15.5B (or $17.5B).
See Straumann Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17.5B | $17.5B | XXX | XXX | XXX | XXX | $3.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Straumann Group has market cap of $17.5B and EV of $17.5B.
Straumann Group's trades at 6.0x LTM EV/Revenue multiple, and 19.3x LTM EBITDA.
Analysts estimate Straumann Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Straumann Group and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $17.5B | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | XXX | XXX |
| EV/EBITDA | 21.4x | XXX | XXX | XXX |
| P/E | 39.9x | XXX | XXX | XXX |
| P/E/Growth | 1.4x | XXX | XXX | XXX |
| EV/FCF | 49.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpStraumann Group's NTM/LTM revenue growth is 10%
Straumann Group's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Straumann Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Straumann Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Straumann Group and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 47% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 39% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 47% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius Medical Care | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Straumann Group acquired XXX companies to date.
Last acquisition by Straumann Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Straumann Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Straumann Group founded? | Straumann Group was founded in 1954. |
| Where is Straumann Group headquartered? | Straumann Group is headquartered in Switzerland. |
| How many employees does Straumann Group have? | As of today, Straumann Group has 11.8K+ employees. |
| Is Straumann Group publicy listed? | Yes, Straumann Group is a public company listed on SWX. |
| What is the stock symbol of Straumann Group? | Straumann Group trades under STMN ticker. |
| When did Straumann Group go public? | Straumann Group went public in 2001. |
| Who are competitors of Straumann Group? | Similar companies to Straumann Group include e.g. Ansell, Polymed, Schott Pharma, Fresenius Medical Care. |
| What is the current market cap of Straumann Group? | Straumann Group's current market cap is $17.5B |
| What is the current revenue of Straumann Group? | Straumann Group's last 12-month revenue is $2.9B. |
| What is the current EBITDA of Straumann Group? | Straumann Group's last 12-month EBITDA is $908M. |
| What is the current EV/Revenue multiple of Straumann Group? | Current revenue multiple of Straumann Group is 6.0x. |
| What is the current EV/EBITDA multiple of Straumann Group? | Current EBITDA multiple of Straumann Group is 19.3x. |
| What is the current revenue growth of Straumann Group? | Straumann Group revenue growth between 2023 and 2024 was 4%. |
| Is Straumann Group profitable? | Yes, Straumann Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
